الفهرس 
Title : A randomized study comparing moxifloxacin, omeprazole, nitazoxanide, and doxycycline versus classic triple therapy for the eradication of helicobacter pylori
AbstractOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
Introduction:Helicobacter pylori infection is a global concern with rising antimicrobial resistance and declining cure rates which has led to an increased demand for a more efficacious, yet tolerable, therapy. Aim: To evaluate the efficacy and safety of the two regimens (Amoxicillin, clarithromycin and omeprazole for 14 days vs moxifloxacin, doxycycline, nitazoxanide and omeprazole for 14 days) as a first-line treatment for Helicobacter pylori (H. pylori) infection. Patients &Methods: from September 2018 to April 2019, 90 patients with confirmed H. pylori infection were randomized into two groups.The First group (triple group)(n = 44) received amoxicillin 1000 mg, clarithromycin500 mg and Omeprazole 40 mg twice a day for 14 days, the Second group (MOND group) (n = 46) received Moxifloxacin 400 mg, Doxycycline 100 mg once daily, Nitazoxanide 500 mg and Omeprazole 40 mg twice a day for 14 days. Successful eradication of H. pylori infection was defined as a negative Stool antigen test 6 weeks after the end of treatment. Patient compliance was defined as 2good3 if drug intake was at least 90%.Follow up of patient’sadherenceto treatment, adverse event rates and dyspepsia improvement was done 6 weeks after theend of treatment